RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboShould read ... European Hematology Association (EHA) 2022 congress
Furthermore Groeneveldt et al. (Leiden University Medical Centre) stated in their findings that ONCY's pelareorep can be used intratumorally or intravenously when combining it with a CD3 bispecific, in prefacing their conclusion below:
"Reovirus as a preconditioning regimen performed significantly better than simultaneous or early administration of CD3-bsAbs. This combination treatment induced regressions of distant lesions that were not injected with reovirus, and systemic administration of both reovirus and CD3-bsAbs also led to tumor control. This suggests that this therapy might also be effective for metastatic disease. Conclusions Oncolytic reovirus administration represents an effective strategy to induce a local interferon response and strong T-cell influx, thereby sensitizing the tumor microenvironment for subsequent CD3-bsAb therapy."